Guidance On Quantitative Thresholds Written-by: Deneen Fumich, RPh As the Pharmaceutical Supply Chain continues to digest the Injunctive Relief requirements for the Big 3 Wholesalers, questions have been posed by industry to both the DEA and State Regulators as to the...
The Increasing Trend of Drug Price Transparency There are presently nineteen states with drug price transparency laws, and an additional ten more...
Even as the COVID-19 pandemic disrupts day-to-day life, drug pricing transparency rages on between consumer groups, regulators, and industry. Regulators are now having to resort to assessing significant fines to increase compliance.
With the developments around COVID-19, the drug manufacturers that working on a cure for the virus have been praised as (potential) saviors across the globe. This is a stark change to how they have regarded over the last few years – drug manufacturers have faced significant scrutiny due to a variety of issues including the opioid epidemic, generic price-fixing and price increases.
The State of Nevada shocked the pharmaceutical supply chain last month by levying an unprecedented $17.4 million in fines due to deficient reporting by drug manufacturers of prescription drugs that are essential for treating diabetes in Nevada.
NY Pharmacies Unite to Take Aim at PBMs Originally published on Nov 29, 2018. Earlier this month over 500 independent pharmacy owners came together...
PBM Pressure: Politics, Prospects and Pass-Throughs Cigna & Express Scripts Follow Aetna & Caremark Lead for Fighting Chance It is no secret...
